Glucagon-like peptide-1 (GLP-1) receptor agonists [10, 13–16] and basal insulin [14, 15, 17] are both choices as pharmaceutical approaches to glycemic treatment for T2DM patients who use metformin alone but nevertheless have poorly controlled glycemia. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.